Presented by:

Prayank Jain
 Chairperson and Managing Director of
Biocon,India’s largest Biotechnology company
 BIOGRAPHY
Born on March 23 , 1953 in Bangalore.

She did schooling from Bishop Cotton Girls School

and Mount Carmel College, Bangalore.

After completing her B.Sc. in zoology from Bangalore

university in 1973, she went to Ballarat University in
Melbourne, Australia and did her masters in Malting
and Brewing.
 HERCARRER
Trainee brewer in Carlton and United Breweries,
Melbourne.

 Trainee maltster at Barrett Brothers and Burston,

Australia.

 Technical consultant at Jupiter Breweries Limited, Calcutta

and as a technical manager at Standard Maltings
Corporation, Baroda between 1975 and 1977.
 THEJOURNEYBEGINS
 She moved to Ireland and joined Biocon Biochemicals
Limited as trainee manager in 1978.

 Founded Biocon India in collaboration with Biocon

Biochemicals Limited.

 Initially working out of her garage, and with only a handful

of rupees in the bank, she began making enzymes for
industrial application, such as papain, a proteolytic enzyme
extracted from the papaya fruit, which prevents chilled
beer from turning hazy.
 KIRAN MAZUMDAR SHAW
Under Kiran Mazumdar Shaw's
Stewardship Biocon transformed
from a industrial enzyme
company to an integrated
biopharmaceutical
company with strategic research
initiatives. Today, Biocon is recognised
as India’s pioneering biotech enterprise.
 BIOCONINDIA
In 1979, Biocon became the first Indian company to
manufacture and export enzymes to USA and Europe.

Biocon is a research driven , global healthcare

company with a strong matrix of capabilities along
the biopharmaceutical value chain.

They believe in strategic licensing partnerships which

rapidly provide wider global access and greater
market penetration.
SUCCESSOFBIOCON
Biocon India Group story began in 1978.
In 1989, Unilever acquired 30% stake.
In 1997, Unilever sold their stake to ICI.
Eventually John Shaw purchased the entire
shareholding from ICI.
In 1994, Syngene International was established to carry
out drug based contract research.
In 2000, Clinigene International was started to
conduct longitudinal clinical studies.
 In 2003, Biocon became the first company worldwide to develop
human insulin on a Pichia express system.

 Biocon creates a buzz in the stock market in March 2004 with its
hugely successful IPO. Day 1on the bourses closes with a market
value of $1.11billion, making Biocon only the second Indian
company to cross the $1 billion mark on the first day of listing.

 In 2007 leading US trade publication, Med Ad News, ranked

Biocon as the 20th leading biotechnology companies in the
world and the 7th largest biotech employer in the world.
 In 2009 received BioSingapore Asia Pacific Biotechnology
Award for Best Listed Company .It has Asia’s largest insulin
and statin facilities as also the largest perfusion-based
antibody production facilities.

 Between 2005 and 2010 Biocon entered into more than 2,200
high-value R&D licensing and other deals within the
pharmaceuticals and bio-pharmaceutical space and helped
Biocon expand its global footprint to emerging and developed
markets through acquisitions, partnerships and in-licensing.

 On November 2012, Biocon become the only Asian Company

to Feature in the Global Top 20 BioPharma Employers, by
Science Magazine.
PRODUCTSAND SERVICES
OFFEREDBYBIOCON
 BIOPHARMACEUTICALS

BIOPHARMACEUTICALS: The Indian Pharmaceutical company

Biocon is capable to meet the country's demand for every drug. The
manufacturing units within the country are meeting about 70% of the
country's drug requirements. The drug production sector is equipped
with technology and researched knowledge base. The company
produces drugs worth rupees 18000 crores and is growing at 9 percent
every year. It offers quality products with internationally accepted
quality standards. There are many production units in India with
products sold at competitive lower prices than international drug
prices.
 ENZYMES

ENZYMES: Biocon is India's largest producer and exporter

of enzymes. It manufactures and markets a broad range of
industrial enzymes, food additives and process aids. Biocon
is the first enzyme company globally to receive the ISO
9001 accreditation. Enzymes manufactured by Biocon are:
Amylases, Cellulases , Catalase , Lipases, Glucanases ,
Phytases , Proteases, and Pectinases .
 CLINICALRESEARCH

CLINICAL RESEARCH : Biocon subsidiary offers global

biotechnology and pharmaceutical majors strong
clinical trial services, regulatory and laboratory
capabilities for clinical drug development. Its value
added services include patient registries and clinical
databases in diabetes, lipidemia , oncology, cardiovascular
diseases.
 CUSTOMRESEARCH

CUSTOM RESEARCH: Biocon subsidiary conduct high

value R&D in early stage drug discovery and
development for a diverse global companies.
 LEADERSHIPSTYLEOFKIRAN
MAZUMDAR SHAW
Kiran Mazumdar Shaw is a transformation leader .She
had a Vision of her own and she is an individualised
type. She never follows what others do or never cares
about what others think.
Kiran Mazumdar Shaw inspires her team with a shared
vision of the future.
Divides the responsibilities amongst their team.
Focussed more on R&D and innovative strategy to
produce new products .
 TRANSACTIONAL AND
TRANSFORMATIONALLEADERSHIP
 In Biocon, both transactional and transformational
leadership has been seen.

 The transactional leaders (or managers) ensure that

routine work is done reliably, while the transformational
leaders look after initiatives that add value.

 High regulating and low nurturing has seen as the key

factor of her behaviour, she always defines the role of the
group members telling them what task to do and how and
when and where to do them. She is the master of her
field so she has developed her trade like that.
PHILANTHROPIC ACTIVITIES
In 2004, she started the Biocon Foundation to conduct
health, education, sanitation, and environment
programs for the benefit of the economically weaker
sections of society. The Foundation’s micro-health
insurance program has an enrolment of 70,000 rural
members

She helped establish a 1,400-bed cancer care center at

the Narayana Health City campus at Boommasandra,
Bangalore, Mazumdar Shaw Cancer Centre
 AWARDS
 ET Businesswoman of the Year, Best
Woman Entrepreneur(2004)
 Ernst & Young's Entrepreneur of the
Year Award for Life Sciences(2002)
 Government of India also felicitated her with
Padmashri (1989) and Padma Bhushan (2005)
 Nikkei Asia Prize, 2009 for Regional Growth
 Express Pharmaceutical Leadership Summit
Award 2009 for Dynamic Entrepreneur
 Business Leader of the Year Award - Biotechnology,
Chemtech-Pharma BioAwards
 World Economic Forum and The Indian Chamber of
Commerce Lifetime AchievementAward
 Received an honorary Doctorate of Science in 2004, from her
alma mater, Ballarat University, in recognition of her pre-
eminent contributions to the field of Biotechnology
 Honorary doctorates from University of Abertay, Dundee, U.K.
(2007), University of Glasgow, U.K. (2008) and Heriot-Watt
University, Edinburgh, U.K. (2008).
Named among TIME magazine’s 100 most influential
people in the world in 2010.
Recognised as the Global Indian (Woman) of the Year
2012 at the 5th Annual Pharmaceutical Leadership
Summit & Business Leadership Awards 2012,India
 CONTROVERSIES
 Air and water pollution in Hebbagodi in Bangalore.
 Death of fishes because of chemical effluent .
 People were suffering from skin disease, headache, kidney failure.

Allegedly violate certain norms of manufacturing

Methylcobalamin.
 Obtained license from the Karnataka government to manufacture
the drug in seven stages
 But during inspection found that the company is importing the
drug from china.
“If you have a vIsIon, a plan and
the conviction, you should
f ollow i t and success w i l l come
your way”
REFERENCES

www.biocon.com
www.wipo.int
www.scribed.com
www.authorstream.com
www.youtube.com